SULTHAN AL RASHID,PREETHA SELVA,V R YASHVANTHAN
DOI: https://doi.org/Objective:To assess the affordability and adherence implications of SGLT-2 inhibitors and GLP-1 analogues in the Indian context, with a focus on Pharmacoeconomics and cost variations
Methods:Medication price data were collected from the Current Index of Medical Specialties (CIMS) and accredited online sources for SGLT-2 inhibitors and GLP-1 analogues from January 2024 to April 2024. Percentage cost variation was calculated to analyse price differences among brands.
Results: SGLT-2 inhibitors, particularly dapagliflozin, exhibited significant price variations, with costs ranging from INR 5.9 to INR 30 per tablet. Combination therapies showed moderate variations, while GLP-1 analogues, including oral semaglutide, were substantially more expensive, ranging from INR 294.81 to INR 387 per tablet.
Conclusion: The study underscores the need for cost-effective prescribing practices to improve affordability and adherence, particularly for resource-constrained settings in India. Integration of these drugs into essential medicine lists and price regulation could alleviate financial strain and enhance accessibility.
